Reader comments on sltrib.com are the opinions of the writer, not The Salt Lake Tribune. We will delete comments containing obscenities, personal attacks and inappropriate or offensive remarks. Flagrant or repeat violators will be banned. If you see an objectionable comment, please alert us by clicking the arrow on the upper right side of the comment and selecting "Flag comment as inappropriate". If you've recently registered with Disqus or aren't seeing your comments immediately, you may need to verify your email address. To do so, visit disqus.com/account.
See more about comments here.
Enzymotec IPO prices at $14 a share, below range
New York » Enzymotec shares soared Friday on their first day of trade as investors snapped up shares of the medical foods maker.
The Israel company sold 4.4 million shares for $14 each. It had expected the shares to price between $16 and $18.
Its shares picked up 23 percent, or $3.20, to $17.20 in morning trading while the broader markets slumped.
Enzymotec Ltd. develops lipid-based nutritional ingredients and medical foods. It plans to use proceeds of $54.9 million for working capital.
The underwriters have the option to buy another 661,800 shares in case of excess demand.
The stock is listed on the Nasdaq Global Select Market under the ticker symbol "ENZY."